Achieve Life Sciences, Inc.: 5%+ holders

As of November 8, 2026, 11 holders' latest Schedule 13D or 13G filings report owning 5% or more of Achieve Life Sciences, Inc. The largest reported stake is Tpg Gp A, LLC's, at 12.6%. 17 filings are on record since July 16, 2025 (Schedule 13D, April 24, 2026).

Who owns Achieve Life Sciences, Inc.?

venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company ↓

Sell to companies like Achieve Life Sciences, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-17 · Reporting person: Logos Global Management LP · Sole voting: 0 · Shared voting: 10,538,440 · Sole dispositive: 0 · Shared dispositive: 10,538,440 · SCHEDULE 13G, 2026-08-17
• Filing 2026-08-13 · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 5,502,064 · Sole dispositive: 0 · Shared dispositive: 5,502,064 · SCHEDULE 13G, 2026-08-13
• Filing 2026-07-28 · Reporting person: Franklin Resources, Inc. · Sole voting: 8,878,942 · Shared voting: 0 · Sole dispositive: 8,878,942 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-07-28
• Filing 2026-07-27 · Reporting person: BlackRock, Inc. · Sole voting: 5,188,710 · Shared voting: 0 · Sole dispositive: 5,271,391 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-27
• Filing 2026-07-08 · Reporting person: Vivo Opportunity Fund Holdings, L.P. · Sole voting: 1,944,430 · Shared voting: 0 · Sole dispositive: 1,944,430 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-08

Achieve Life Sciences, Inc. has 17 Schedule 13D or 13G filings on record since 2025-07-16. 11 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Achieve Life Sciences, Inc. and the warning signs.

See Achieve Life Sciences, Inc.'s free Snapshot Watch Achieve Life Sciences, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Achieve Life Sciences, Inc. and the records around it.

Achieve Life Sciences, Inc. elsewhere on the record

• Leadership changes Jun 2026
• Who owns it

Companies that share a holder

• venBio Global Strategic Fund V, L.P. also filed stake reports on 1 other company: Yarrow Bioscience, Inc. (Aug 2026)
• Logos Global Management LP also filed stake reports on 14 other companies: Longeveron Inc. (Sep 2026), Yarrow Bioscience, Inc. (Aug 2026), Avalo Therapeutics, Inc. (May 2026)
• TPG GP A, LLC also filed stake reports on 15 other companies: Allogene Therapeutics, Inc. (Sep 2026), TPG Inc. (Aug 2026), Ceribell, Inc. (Aug 2026)

Want the whole picture on Achieve Life Sciences, Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Achieve Life Sciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Achieve Life Sciences, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   21 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Achieve Life Sciences, Inc. by CUSIP 004468500 and gives its principal executive office as 22722 29TH DR. SE, SUITE 100, SEATTLE, WA 98021 (SCHEDULE 13G, 2026-08-17).

Purpose of Transaction (Item 4)

Tpg Gp A, LLC

The information set forth in or incorporated by reference in Items 2, 3, 5 and 6 of this Schedule 13D is incorporated by reference in its entirety into this Item 4. Securities Purchase Agreement TPG Auriga entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with the Issuer, dated as of April 15, 2026, pursuant to which it agreed to purchase, and the Issuer agreed to sell and issue, 6,877,580 shares of Common Stock and 6,877,580 accompanying Warrants at a collective price of $3.635 per combination of share of Common Stock and accompany Warrant (the "Private Placement"). On April 17, 2026, the Private Placement closed (the "Closing"). The aggregate purchase price of $25,000,003.30 paid by TPG Auriga for the shares of Common Stock and accompanying Warrants was funded by equity contributions of the limited partners of TPG Auriga. Pursuant to the Securities Purchase Agreement, on April 15, 2026, the Board of Directors of the Issuer appointed Lucian Iancovici, as designated by TPG Auriga, to serve as a director of the Issuer, effective April 17, 2026. The Issuer has agreed to nominate Dr. Iancovici for re-election to the Board of Directors at the Issuer's 2026 annual meeting of stockholders and the 2027 annual meeting of stockholders, until such time as TPG Auriga beneficially owns less than 5% of the Issuer's outstanding Common Stock. Registration Rights Agreement In connection with the Private Placement, TPG Auriga entered into a …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-24; the filing has the rest

venBio Global Strategic Fund V, L.P.

The response to Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Persons acquired the securities reported herein for investment purposes. Subject to a number of factors, including market conditions and their general investment and trading policies, the Reporting Persons may, in the ordinary course of their business, dispose of the shares of Common Stock that they beneficially own. These dispositions may occur in open market transactions, privately negotiated transactions, or through other methods. Additionally, Fund V may distribute the shares of Common Stock that it directly holds to its limited partners. Dr. Royston, who is a member of General Partner V, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Dr. Royston, may engage in discussions from time to time with the Board, the Issuer's management, or the Issuer's other stockholders. These discussions may be with respect to (i) acquiring or disposing shares of Common Stock or other securities of the Issuer (collectively, the "Securities"); (ii) maintaining or changing the Issuer's business, operations, governance, management, strategy, or capitalization; or (iii) implementing transactions that may relate to or may result in any matter set forth in paragraphs (a) through (j) of the instructions to Item 4 of Schedule 13D. Additionally, the Reporting Persons may acquire additional Securities through open market transactions, privately negotiated …The first part of Item 4 of the SCHEDULE 13D filed 2026-04-27; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns Achieve Life Sciences, Inc.

Who owns Achieve Life Sciences, Inc.?

On this page, 11 holders' latest ownership filings report 5% or more of Achieve Life Sciences, Inc.: Tpg Gp A, LLC (12.6%, Schedule 13D, filed 2026-04-24), venBio Global Strategic Fund V, L.P. (9.99%, Schedule 13D, filed 2026-04-27), Logos Global Management LP (9.99%, Schedule 13G, filed 2026-08-17), Paradigm BioCapital Advisors LP (9.2%, Schedule 13G, filed 2026-04-24) and Franklin Resources, Inc. (8.3%, Schedule 13G/A, filed 2026-07-28); 6 more are listed above.

Who are the largest shareholders of Achieve Life Sciences, Inc.?

By the share each holder's latest filing reports, the largest holders of Achieve Life Sciences, Inc. on this page are Tpg Gp A, LLC (12.6%), venBio Global Strategic Fund V, L.P. (9.99%) and Logos Global Management LP (9.99%).

When did Tpg Gp A, LLC buy into Achieve Life Sciences, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Tpg Gp A, LLC on this page is the Schedule 13D, filed 2026-04-24, reporting 12.6%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 17 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Achieve Life Sciences, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Achieve Life Sciences, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Achieve Life Sciences, Inc. is mentioned again
• Find former Achieve Life Sciences, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes